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Abstract
INTRODUCTION: The CD95/CD95L pathway plays a critical role in tissue homeostasis and immune system regula-
tion; however, the function of this pathway in malignancy remains poorly understood. We hypothesized that CD95L
expression in esophageal adenocarcinoma confers advantages to the neoplasm other than immune privilege.METH-
ODS: CD95L expression was characterized in immortalized squamous esophagus (HET-1A) and Barrett esophagus
(BAR-T) cells; adenocarcinoma cell lines FLO-1, SEG-1, and BIC-1, and MDA468 (− control); and KFL cells (+ control).
Analyses included reverse transcription–polymerase chain reaction, immunoblots of whole cell and secretory vesicle
lysates, FACScan analysis, laser scanning confocal microscopy of native proteins and fluorescent constructs, and
assessment of apoptosis and ERK1/2 pathways. RESULTS: Cleaved, soluble CD95L is expressed at both the RNA and
protein levels in these cell lines derived from esophageal adenocarcinoma and other human tissues. CD95L was
neither trafficked to the cell membrane nor secreted into the media or within vesicles, rather the protein seems
to be sequestered in the cytoplasm. CD95 and CD95L colocalize by immunofluorescence, but an interaction was
not proven by immunoprecipitation. Overexpression of CD95L in the adenocarcinoma cell lines induced robust
apoptosis and, under conditions of pan-caspase inhibition, resulted in activation of ERK signaling. CONCLUSIONS:
CD95L localization in EA cells is inconsistent with the conference of immune privilege and is more consistent with a
function that promotes tumor growth through alternative CD95 signaling. Reduced cell surface expression of CD95
affects cell sensitivity to extracellular apoptotic signals more significantly than alterations in downstream modulators
of apoptosis.
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Introduction
The importance of alterations in apoptotic pathways to the develop-
ment of malignancy is well established. CD95 (Fas/Apo-1) is a cell
surface receptor and member of the “death receptor” family that in-
cludes the tumor necrosis factor receptors (TNFR1 and TNFR2),
DR4 and DR5, and TRAIL [1,2]. Normally, CD95 transmits an apop-
totic signal after binding by CD95 ligand (CD95L) [3]. Consistent
with this function, near-universal resistance to CD95-mediated apop-
tosis has been observed in many malignancies [4]. However, loss of
expression or inactivating mutation of CD95 is rarely observed in
neoplasia [4]. In fact, activation of CD95 and other family members
has been observed to stimulate p38, nuclear factor κB (NF-κB), and
extracellular signal–regulated kinase 1/2 (ERK1/2) activities, and
accumulating evidence suggests a potential role for CD95/CD95L
pathway involvement in tumor development [5–7]. Very recently,
Chen et al. [8] clearly demonstrated a role for CD95 in the pro-
motion of tumor growth through a pathway involving the mitogen-
activated protein kinases (MAP-k) JNK and Jun.
The CD95/CD95L system plays an essential role in T-cell devel-
opment, and CD95L expression produces immune privilege in the
placenta, testis, and the anterior chamber of the eye [9–11]. CD95L
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is also expressed by neoplastic tissues, and cancer patients frequently
have elevated levels of CD95L [12–15]; however, acceptance of an im-
mune privilege function of neoplastic CD95L expression remains con-
troversial owing to conflicting experimental data [16,17]. Recent data
have improved our understanding of the functions of membrane-
bound CD95L (mCD95L) versus protease-cleaved soluble CD95L
(sCD95L) showing that mCD95L only is essential for CD95-mediated
apoptosis [18]. However, there remains a lack of adequate data re-
garding the expression and function of sCD95L versus mCD95L
in neoplasia.
We have previously identified resistance to CD95-mediated apop-
tosis in esophageal adenocarcinoma (EA) and lung non–small cell
cancer due to cytoplasmic retention of CD95 resulting in reduced
cell surface expression [19,20]. Given the above background, we hy-
pothesized that CD95 ligand expression in EA confers advantages
other than immune privilege to the cell. The aims of this study were
1) to characterize posttranslational regulation and localization of
CD95L expression in EA, 2) to determine whether cytoplasmic
CD95-CD95L interactions occur in EA, and 3) to investigate the re-
sponse of EA cells to activation of the cytoplasmic pool of CD95.
We discovered that EA cells produce CD95L but relatively lack
mCD95L expression, lack secretion of sCD95L, and provide data
suggesting low levels of sCD95L expression in EA results in alterna-
tive MAP-k signaling. Most importantly, overexpression of CD95L
within the cytoplasm of CD95-mediated apoptosis-resistant adeno-
carcinoma cells induces extensive apoptosis. This finding strongly
suggests that posttranslational regulation of cell surface expression
of death receptors affects cell sensitivity to extracellular apoptotic sig-




All cell lines are human derived. The following cells were pur-
chased from American Type Culture Collection (ATCC, Manassas,
VA): Het-1A (squamous esophagus), Jurkat T cells ( JTCs), and
MDA468 (breast adenocarcinoma). The three adenocarcinoma cell
lines (Seg-1, Bic-1, and Flo-1) have been previously described [19].
Since this earlier report, we have learned that only Flo-1 cells are of
EA origin. DNA fingerprinting has demonstrated that Seg-1 cells are
actually H460 lung adenocarcinoma cells, and Bic-1 cells are SW480
colon adenocarcinoma cells (D.G. Beer, personal communication).
KFL (leukemia) [21] and BAR-T Barrett esophagus cells [22] were
generous gifts from Drs David Kaplan and Rhonda Souza, respectively.
Cell lines were maintained in RPMI-1640 (KFL, JTC, Het-1A,
and Seg-1) or Dulbecco modified Eagle media (MDA468, Bic-1,
and Flo-1) (BioWhittaker, Walkersville, MD) which were supple-
mented with 10% fetal bovine serum (Atlanta Biologicals, Norcross,
GA), 1% penicillin/streptomycin, and 1% L-glutamine (Invitrogen,
Carlsbad, CA). Barrett esophagus was maintained as previously de-
scribed [22]. All cell lines were propagated in a humidified environ-
ment at 37°C with 5% CO2.
Antibodies and Reagents
The following antibodies for immunoblot analysis were purchased
from Santa Cruz Biotechnology, Inc (Santa Cruz, CA): constitutive
heat shock protein 70 (Hsc70), ERK, and phospho-ERK. Other
antibodies used for immunoblot analysis included caspase 8 and
caspase 3 (Cell Signaling Technology, Inc, Beverly, MA), CD95 clone
5F-7 (Kamiya Biomedical Company, Seattle, WA), and β-actin
(Sigma-Aldrich, Inc, St Louis, MO). Anti-CD95 clone CH11 (Upstate
Biotechnology, Inc, Lake Placid, NY) was used for laser scanning
confocal microscopy and apoptosis induction, and green fluorescent
protein (GFP) and bovine serum albumin (BSA) antibodies (Abcam,
Inc, Cambridge, MA) were used for immunoprecipitation. Anti-
CD95L antibody clones NOK-1 and G247-4 (Becton Dickinson
Pharmingen, San Diego, CA) were used for FACScan analysis of cell
surface expression and immunoblot analysis/laser scanning confocal
microscopy, respectively. All horseradish peroxidase– and fluorophor-
conjugated secondary antibodies were purchased from Jackson Im-
munoresearch, Inc (West Grove, PA), and Draq5 was purchased from
Biostatus, Ltd (Leicestershire, UK). The broad-spectrum matrix metal-
loproteinase (MMP) inhibitor GM-6001 and the pan-caspase inhibitor
Z-VAD-FMK (zVad) were purchased from Chemicon International,
Inc, (Temecula, CA) and Promega (Madison, WI), respectively.
CD95L and CD95 Reverse Transcription–Polymerase
Chain Reaction
RNAwas isolated from90%confluent cultures using theRNEasyMini
Kit (Qiagen, Valencia, CA), and 2 μg of RNA was reverse-transcribed
using theOne StepRT-PCRKit (Qiagen) according to themanufacturer’s
instructions. CD95L forward primer was 5′-GCCCTTCAATTACCCA-
TATCCC-3′, and CD95L reverse primer was 5′-GGCAACCAGAAC-
CATGAAAAACA-3′. Initial conditions for both reactions included a
reverse transcription at 50°C for 30 minutes and a polymerase chain re-
action (PCR) activation step at 95°C for 15 minutes. For CD95L, this
was followed by 35 cycles consisting of a 1-minute denaturation at
94°C, 1-minute annealing at 62°C, and a 1-minute extension at 72°C.
Reactions were carried out using a Stratagene Mx3000P QPCR Sys-
tem (Stratagene, La Jolla, CA). Ten microliters of PCR product was
then size-fractionated on a 2% agarose gel containing ethidium bromide
(Sigma-Aldrich, Inc) and photographed under ultraviolet light.
Adenoviral Vector Construction and Infection
The adenoviral (Ad)-CD95L and Ad-CD95L-GFP constructs have
previously been described [23]. For the construction of Ad-CD95-
GFP, full-length human CD95 cDNA was generated as described
above. GFP was attached to the carboxy-terminus of CD95 by cloning
the PCR product into the pcDNA3.1/CT-GFP-TOPO vector accord-
ing to the manufacturer’s instructions (Invitrogen). After selection of
positive clones, appropriate orientation of the insert was verified by the
DNA Sequencing Core Facility at the University of Pittsburgh using
the T7 and GFP Reverse primers supplied by Invitrogen. E1- and E3-
deleted Ad-CD95-GFP was constructed through Cre-lox recombina-
tion as previously described [24]. Briefly, the CD95-GFP construct was
inserted into the shuttle vector pAdlox, and Ad-CD95-GFP was gen-
erated by cotransfection of Sfi I–digested pAdlox-CD95-GFP and Ψ5
helper virus DNA into the Ad– packaging cell line CRE8. Recombi-
nant adenoviruses were propagated on CRE8 or 293 cells and purified
by cesium chloride density gradient centrifugation and subsequent
dialysis. Titers of viral particles were determined by optical densitom-
etry, and 100 particles were estimated to represent 1 PFU. Optimal
multiplicity of infection (MOI) was determined using Ad-eGFP and
measuring the percentage fluorescent cells 24 and 48 hours later. Ap-
proximately 90% transduction was achieved with MOI 100 in Seg-1
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and Flo-1 and MOI 50 in MDA468. For all experiments, cells were
infected for 6 hours at 37°C in 5% CO2 using an MOI of 50.
Immunoblot Analysis and Immunoprecipitation
For immunoblot analysis, protein was extracted from subconfluent
cultures using lysis buffer (Cell Signaling Technology, Inc) containing
1 mM phenylmethlsulfonylfluoride (Sigma-Aldrich, Inc) and quan-
tified using the BCA protein assay kit (Pierce, Rockford, IL). For
immunoprecipitation, cells were first infected with either empty ad-
enovirus (Ad-Ψ5), Ad-CD95-GFP, or Ad-CD95L-GFP as described
above. Antibodies were conjugated to Protein-G beads according to
the Sigma Protein-G Immunoprecipitation Kit manufacturer’s in-
structions (Sigma-Aldrich, Inc), cell lysate was added to the antibody-
conjugated beads, and the mixture was tumbled end-over-end at 4°C
for 3 hours. The immunoprecipitate was then centrifuged three times
at 16,000g, washed with PBS, mixed with sample buffer, and boiled
for 5 minutes in preparation for immunoblot analysis. Proteins were
resolved using sodium dodecyl sulfate–polyacrylamide gels and sub-
sequently transferred to nitrocellulose membranes (Bio-Rad, Hercules,
CA). Membranes were blocked in 5%milk solution, incubated with pri-
mary antibody, washed, and incubated with horseradish peroxidase–
conjugated secondary antibody. Immunoreactivity was detected using
SuperSignal West Pico Chemiluminescent Substrate (Pierce) and x-ray
film (Eastman Kodak, Rochester, NY). Blots were stripped with 2%
sodium dodecyl sulfate, 100 mM β-mercaptoethanol, and 62.5 mM
(pH 6.8) Tris (Sigma-Aldrich, Inc) for 20 minutes at 53°C and re-
probed with control antibody.
FACScan Analysis of CD95L Expression and Apoptosis
For analysis of CD95L cell surface expression, subconfluent cultures
were incubated for 24 hours in the presence or absence of the broad-
spectrum MMP inhibitor GM-6001 (100 μM), harvested with PBS/
10 mM EDTA (Sigma-Aldrich, Inc), resuspended in PBS/0.5%
normal rabbit serum (Sigma-Aldrich, Inc), and blocked on ice for
15 minutes. Cells were subsequently labeled with anti-CD95L clone
NOK-1 antibody and FITC-conjugated secondary antibody (1:200)
for 30 minutes each and maintained on ice until analysis. For apopto-
sis studies, subconfluent cultures were either treated with anti-CD95
activating antibody clone CH11 (20 ng/ml) or infected with Ad-Ψ5 or
Ad-CD95L in the presence or absence of the pan-caspase inhibitor
zVad (50 μM). Cells were then harvested as described above and
stained using the annexin V–FITC apoptosis detection kit (BD Bio-
sciences, San Diego, CA) per the manufacturer’s instructions. CD95L
expression and apoptosis were assessed by flow cytometry using a
Becton Dickinson FACSort (San Jose, CA), and data were analyzed
using WinMDI software (Scripps Research Institute, La Jolla, CA).
CD95L ELISA and Isolation of Vesicles
For CD95L ELISA, cells were seeded at 4 × 105 per dish and
allowed to proliferate for 5 days (without a medium change). Me-
dium was then collected, and debris were pelleted by centrifugation
at 1000g for 5 minutes. The supernatant (media) was concentrated
50-fold using Centricon YM-10 filters (Fisher Scientific, Pittsburgh,
PA), and soluble CD95L (sCD95L) expression was analyzed by com-
mercially available ELISA (R&D Systems, Minneapolis, MN) ac-
cording to the manufacturer’s instructions. For isolation of vesicles,
supernatant (media) was recovered from subconfluent cultures and
was subjected to three successive centrifugations at 300g (5 minutes),
1200g (20 minutes), and 10,000g (30 minutes) to eliminate cells and
debris, followed by centrifugation for 1 hour at 100,000g. To remove
excess serum proteins, the vesicle pellet was washed with a large vol-
ume of PBS, centrifuged at 100,000g for 1 hour, and finally resus-
pended in 100 μl of PBS. Protein was then quantified and examined
by immunoblot analysis as described above.
Laser Scanning Confocal Microscopy
Cells were plated on glass coverslips and allowed to reach 50%
confluence. For CD95L microscopy, cells were then fixed with 2%
paraformaldehyde, permeabilized with 1% Triton-X, and blocked for
45 minutes in a 1:20 dilution of normal goat serum (Sigma-Aldrich,
Inc) in PBS. After several washes with 0.1% BSA (Sigma-Aldrich, Inc),
the coverslips were maintained on ice and labeled with either anti-
CD95L clone G247-4 (1:100) or anti-CD95 clone CH11 (1:100) fol-
lowed by Cy3-conjugated secondary antibody (1:1000) for 1 hour
each. Nuclei were stained with Draq5 for 5 minutes (1:1000), and
coverslips were mounted with gelvatol and stored overnight at 4°C.
For dual (CD95/CD95L) staining, 50% confluent cells were first in-
fected with either Ad-CD95-GFP or Ad-CD95L-GFP and then
stained as described above. Cells were viewed the following day using
an Olympus FluoView 1000 confocal microscope (Olympus, Inc,
Center Valley, PA).
Results
CD95L Is Expressed in a Variety of Human Cell Lines
CD95L expression has previously been demonstrated in surgical
specimens of esophageal and other adenocarcinomas [25], but the ex-
pression of CD95L in adenocarcinoma cell lines has not been well
characterized. CD95L mRNA was detected in all five human cell lines
including immortalized HET-1A and BAR-T cells (Figure 1A). By im-
munoblot, both the membranous (34 kDa) and soluble (21 kDa)
forms of CD95L were detected in the positive control KFL cells,
whereas in most experiments, only sCD95L was observed in the other
cell lines (Figure 1B). Comparatively small quantities of mCD95L
were occasionally observed in Flo-1 and Seg-1 cells. CD95L protein
expression was greatest in the positive control KFL and adenocarci-
noma Seg-1 cell lines, with slightly lower levels of CD95L protein
observed in Bic-1 cells. The CD95L protein level detected in Flo-1
cells was similar to that observed in the immortalized Het-1A and
BAR-T cell lines. Taken together, our in vitro observations are consis-
tent with the previously reported in situ expression of CD95L in
esophageal, colon, and lung adenocarcinomas [25–27], validating
these cell lines as models consistent with surgical specimens.
CD95L Is Not Trafficked to the Cell Membrane
Increased expression of CD95L is putatively advantageous to tu-
mors through down-regulation of the immune response through in-
duction of apoptosis in tumor-infiltrating lymphocytes (TILs), a
concept coined the “counterattack hypothesis” [13]. Because we ob-
served the soluble form (sCD95L) expressed by the adenocarcinoma
cell lines, we hypothesized that CD95L is trafficked to the cell mem-
brane and secreted. To the contrary, we were unable to demonstrate
cell surface expression of CD95L, even after MMP inhibition in any
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of the cell lines (Figure 2A). Furthermore, ELISA did not identify the
presence of secreted CD95L in the culture medium (Figure 2B).
Regulation of CD95L expression is complex and is determined
not only by transcriptional and translational activity but also through
posttranslational processing [28,29]. Secretion of CD95L inmembrane-
bound vesicles by neoplasms has been described [30]. Thus, we
investigated the hypothesis that the observed CD95L was being pack-
aged into vesicles for secretion. Vesicle production was observed
in the EA cell line Flo-1 and, to a far lesser extent, in Seg-1 adeno-
carcinoma cell line based on protein quantification of the isolated
vesicles (data not shown), yet CD95L was not detectable in the iso-
lated vesicles (Figure 2C ). Furthermore, laser scanning confocal mi-
croscopy demonstrated cytoplasmic expression of CD95L in the
Flo-1 cell line (Figure 2D). Taken together, these observations sug-
gest that adenocarcinoma cells sequester cleaved, sCD95L in the cyto-
plasm and do not traffic the protein to the cell membrane or secrete
it through vesicles.
Figure 1. CD95L expression in a panel of human cell lines. (A) Re-
verse transcription–polymerase chain reaction analysis of CD95L
mRNA expression. (B) Immunoblot analysis of CD95L protein ex-
pression using the G247-4 antibody. mCD95L was detected only
in KFL cells, whereas sCD95L was expressed by all cell lines ex-
amined. Results are representative of at least three individual ex-
periments. NTC indicates no template control.
Figure 2. Subcellular localization of CD95L. (A) FACScan analysis of
CD95L cell surface expression (shaded histograms represent no pri-
mary antibody controls; open histograms represent experimental
groups in the absence [solid lines] or presence [dashed lines] of
MMP inhibition). Cell surface expression of CD95L was not de-
tected in any of the esophageal or adenocarcinoma cell lines, even
after MMP inhibition. (B) CD95L ELISA of culture medium. Data are
presented as mean concentration (ng/ml) ± SEM of three individual
experiments. Secretion of CD95L by the esophageal and adenocar-
cinoma cell lines was negligible or absent. (C) Immunoblot of CD95L
expression in whole cell lysates and vesicle preparations from the
adenocarcinoma cell lines Seg-1 and Flo-1. Vesicles were detected
and isolated from Flo-1 cells and to a lesser degree from Seg-1 cells
(as evidenced by Hsc70 immunoreactivity [36]), but CD95L was
not detected by immunoblot analysis these vesicle preparations.
(D) Laser scanning confocal microscopy of CD95L in the EA cell line
Flo-1 (magnification, ×400). CD95L is predominantly localized to the
cytoplasm in a perinuclear distribution.−/+ indicates represents no
primary antibody control; blue, nuclei; red, CD95L. All results are
representative of at least three individual experiments.
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Intracellular CD95-CD95L Interactions
Combined with our previously reported cytoplasmic retention of
CD95 in Flo-1 cells [19], these current observations led us to hy-
pothesize that intracellular CD95-CD95L interactions may be occur-
ring. For these studies, we used a fusion protein strategy whereby
either CD95 or CD95L was conjugated to GFP and delivered using
E1 and E3 deleted adenoviral infection. Similar to the expression of
native CD95 and CD95L in these cells, both the Ad-CD95-GFP
and Ad-CD95L-GFP constructs resulted in predominantly cyto-
plasmic expression of CD95 and CD95L; furthermore, a moderate
degree of colocalization was apparent (Figure 3A). However, we were
unable to demonstrate an interaction by immunoprecipitation of GFP
after infection with Ad-CD95-GFP (Figure 3B) or Ad-CD95L-GFP
(data not shown). Thus, whereas there is a degree of colocalization,
we were unable to demonstrate an intracellular CD95-CD95L pro-
tein interaction.
Expression of Cytoplasmic CD95L Overcomes Resistance
to CD95-Mediated Apoptosis
Given the altered expression and potential cytoplasmic interaction
of CD95 and CD95L in Flo-1 cells, we hypothesized that stimula-
tion of the intracellular pool of CD95 would result in alternative sig-
naling. JTCs, which abundantly express CD95 on the cell membrane
[31], are sensitive to extracellular CD95 stimulation and served as a
positive control. CD95-null MDA468 cells served as a negative con-
trol [32]. Treatment with activating anti-CD95 antibody (CH11) in-
duced apoptosis only in JTC and, to a lesser extent, in Seg-1 cells.
Surprisingly, overexpression of cytoplasmic CD95L (after treatment
with Ad-CD95L) induced robust apoptosis in Seg-1 and Flo-1 cells
leading to complete loss of the cultures, and this response was inhib-
ited by zVad (Figure 4, A and B). Neither activating anti-CD95 anti-
body nor Ad-CD95L resulted in apoptosis in CD95-null MDA468
cells. Apoptosis was further confirmed by immunoblot analysis for
cleaved caspase 8 and caspase 3 in the EA cell line Flo-1 (Figure 4C ).
Importantly, these findings show that overexpression of cytoplasmic
CD95L induces extensive apoptosis in otherwise CD95-resistant ade-
nocarcinoma cells.
Several reports have demonstrated that CD95 signaling may also
result in activation of nonapoptotic signaling pathways [5–8]. Because
pan-caspase inhibition with zVad inhibited Ad-CD95L–induced apop-
tosis, we hypothesized that CD95-CD95L interactions under these
circumstances would result in nonapoptotic signaling. Extracellular-
regulated kinase (ERK) was phosphorylated in untreated Flo-1 cells,
and none of the treatments alone (activating anti-CD95 antibody, con-
trol virus, or Ad-CD95L) resulted in significant ERK phosphorylation.
In the presence of pan-caspase inhibition, however, treatment with
Ad-CD95L induced robust phosphorylation of ERK (Figure 4D).
We attempted to further confirm that CD95-CD95L interactions
contribute to constitutive MAP-k signaling by determining the effects
of silencing CD95L mRNA expression but failed because of small
interfering RNA transfection efficiency and other challenges. Thus,
in the setting of downstream (pan-caspase) inhibition of apoptosis
pathways and overexpression of CD95L, cytoplasmic CD95-CD95L
Figure 3. Intracellular interaction of CD95 and CD95L. (A) Laser
scanning confocal microscopy of CD95 and CD95L in Flo-1 cells af-
ter infection with either Ad-CD95-GFP (left column) or Ad-CD95L-GFP
(right column) as described in Materials andMethods (magnification,
×400). In the left column, CD95 appears green and CD95L appears
red, whereas CD95 appears red and CD95L appears green in the
right column. Similar to the expression of the native proteins, both
Ad-CD95-GFP and Ad-CD95L-GFP predominantly localize in the cyto-
plasm. A modest degree of CD95-CD95L colocalization was appar-
ent after infection with both adenoviral constructs. (B) Immunoblot
of CD95 and CD95L in Flo-1 cells after infection with Ad-CD95-GFP
and immunoprecipitation of GFP. GFP immunoprecipitation was con-
firmed by detection of CD95 at an expected, slightly larger molecular
weight, but neither mCD95L nor sCD95L was coprecipitated. Non-
specific immunoprecipitate bands in the CD95L immunoblot rep-
resent BSA antibody light chain (Control) and GFP antibody light
chain (Ad-Ψ5 and Ad-CD95-GFP). Results are representative of three
individual experiments.
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interactions result in activation of nonapoptotic signaling pathways,
but a role for low-level CD95-CD95L interactions contributing to
constitutive MAP-k signaling could not be confirmed.
Discussion
We have shown that CD95L is expressed at both the RNA and pro-
tein levels in a panel of cell lines derived from EA and other hu-
man tissues. Size-fractionation suggests the protein is predominantly
cleaved to sCD95L; mCD95L was relatively absent by immunoblot
or FACScan analysis or laser scanning confocal microscopy. CD95L
was neither trafficked to the cell membrane nor secreted into the me-
dium or within vesicles, rather the protein seems to be sequestered in
the cytoplasm. CD95 and CD95L colocalize by immunofluorescence,
but an interaction could not be demonstrated by immunoprecipi-
tation. Overexpression of CD95L in the EA cell line Flo-1 induced
robust apoptosis and under conditions of pan-caspase inhibition, re-
sulted in activation of ERK signaling. Taken together, our findings
imply that CD95L expression by neoplasms may confer prosurvival
and proliferation functions; however, these end points were not spe-
cifically shown. Furthermore, the robust induction of apoptosis after
overexpression of CD95L, confined to the cytoplasm, suggests that
the posttranslational regulation of cell surface levels of death recep-
tors is an important mechanism of resistance to extracellular apopto-
tic signals.
These findings are inconsistent with previous reports suggesting
an immune privilege function of CD95L expression in esophageal
cancer through induction of apoptosis in TILs [25,33]. We were un-
able to demonstrate cell surface expression of CD95L in any of our
cell lines, even after treatment with a MMP inhibitor (Figure 2A).
Reports have supported a role for modulation of tumoral immunity
in melanoma and head and neck cancer where secretion of CD95L in
membrane-bound vesicles has been suggested to result in modulation
of the immune system in tumor-bearing host [30]. CD95L protein
Figure 4. Effects of extracellular compared with intracellular stimulation of CD95. (A) FACScan analysis of annexin V (AV)– and propidium
iodide (PI)–stained JTC and Flo-1 cells 24 hours after treatment with activating CD95 antibody (CH11), control virus (Ad-Ψ5), or Ad-CD95L
in the presence or absence of the pan-caspase inhibitor zVad. Positive staining for AV suggests early apoptosis (right lower quadrant).
Positive staining for PI suggests loss of membrane integrity late in apoptosis (right upper quadrant) or due to necrosis (left upper quad-
rant). CH11 induced massive cell death in CD95-sensitive JTC but had no effect in Flo-1 cells, whereas Ad-CD95L induced cell death in
Flo-1. Addition of zVad inhibited cell death induced by both CH11 (JTC) and Ad-CD95L (Flo-1), suggesting that these treatments induce
apoptosis. (B) Bar graph depicting percent apoptosis in CD95-null MDA468 cells and the adenocarcinoma cell lines Seg-1 and Flo-1 after
treatments as described above. Data are presented as mean percent apoptosis (sum of % AV-positive and % AV/PI-positive cells) ±
SEM of three individual experiments. Neither CH11 nor Ad-CD95L induced apoptosis (compared with controls) in MDA468 cells. CH11
induced apoptosis in Seg-1 but not Flo-1 cells, whereas Ad-CD95L resulted in apoptosis in both adenocarcinoma cell lines. (C) Immu-
noblots of caspase 8 and caspase 3 in JTC and Flo-1 cells after treatments as described above. CH11 induced caspase 8 and caspase 3
cleavage in JTC but not Flo-1 cells, whereas Ad-CD95L induced cleavage of both caspase 8 and caspase 3 in Flo-1 cells. Caspase cleav-
age was attenuated by zVad after both treatments. C indicates control; V, vehicle (DMSO). (D) Immunoblots of phosphorylated ERK
(p ERK) and total ERK in Flo-1 cells after treatments as described above. ERK was phosphorylated in control (C) cells, and infection with
Ad-CD95L (in the presence of zVad) induced further phosphorylation of ERK.
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was not present in isolated secretory vesicles from Seg-1 and Flo-1
cells (Figure 2C ). Thus, our findings are not consistent with CD95L
expression in EA contributing to direct effects on TILs or the circulating
cytokine mileu. Finally, given a recent report showing mCD95L is es-
sential for CD95-induced apoptosis [18], our observation of sCD95L
protein and the lack of mCD95L indirectly supports the notion of
a nonapoptotic function of CD95L expression in adenocarcinoma.
Our previously reported observation of cytoplasmic retention of
CD95 in these same cell lines [19] led us to postulate that CD95L
expression and intracellular CD95-CD95L interactions contributed
to this phenotype. Because of reagent limitations that affect dual la-
beling and immunoprecipitation of the native proteins, we used a
GFP fusion protein strategy. We were unable to demonstrate an in-
teraction by immunoprecipitation, but this may represent a techni-
cal problem or a low-affinity protein-protein interaction, as laser
scanning confocal microscopy suggested a modest degree of colocali-
zation (Figure 3). Furthermore, Ad-CD95L induced robust apoptosis
within 6 hours of infection in all cell lines except for CD95-null
MDA468 cells (Figure 4B). This finding supports the hypothesis that
CD95L is capable of interacting with the cytoplasmic pool of CD95
and demonstrating that the apoptotic machinery downstream of
CD95 is intact. This has important implications regarding regulation
of cell sensitivity to extracellular signaling for apoptosis. This finding
demonstrates that decreased cell surface expression alone is sufficient to
render cells resistant to CD95-mediated apoptosis, and this mecha-
nism may have been underappreciated in other studies that focus on
downstream modulation of apoptotic pathways.
Our observation of increased ERK1/2 phosphorylation after Ad-
CD95L infection supports the notion that CD95L expression may
confer functions beneficial to neoplasia and is consistent with the
findings of others [5–8]. CD95 signaling has been shown to be impor-
tant for hepatocyte regeneration after hepatectomy [34] and neurite
outgrowth after injury [35]. Furthermore, there are reports of activa-
tion of NF-κB, p38, and ERK1/2 in various tumor cell lines leading to
proliferation and tumor progression [5–7]. In Flo-1 EA cells, ERK1/2
was constitutively phosphorylated, and this was further enhanced after
CD95 activation with Ad-CD95L but only under conditions of pan-
caspase inhibition (Figure 4D). Thus, our data are consistent with
growing evidence of nonapoptotic functions for CD95 under condi-
tions of dysfunctional downstream apoptotic signaling that may confer
advantages to tumor cells and help explain the observed absence of
mutations or loss of expression of CD95 in neoplasia.
In summary, we have documented CD95L expression in a panel of
human esophageal and various adenocarcinoma cell lines. Similar to
CD95 expression in these cell lines, CD95L was sequestered in the
cytoplasm. Stimulation of the intracellular pool of CD95 induced
robust apoptosis in otherwise CD95-resistant Flo-1 cells and resulted
in ERK activation under conditions of pan-caspase inhibition. Thus,
posttranslational regulation of cell surface expression of death recep-
tors is an important modulator of cell sensitivity to external signals
for apoptosis. Our data support the potential for therapies aimed at
increasing cytoplasmic CD95L expression in CD95-resistant cells
and support the concept that, under certain conditions, CD95 stim-
ulation may result in activation of nonapoptotic signaling pathways.
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